COMMUNIQUÉS West-GlobeNewswire

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
12/06/2026
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145, on track for IND [...]
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
12/06/2026
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621 parallel Phase 2b [...]
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
12/06/2026
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status [...]
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
12/06/2026
PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
12/06/2026
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical [...]
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
12/06/2026
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of Phase [...]
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
12/06/2026
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to [...]
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
12/06/2026
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo 1 , with favorable safety profile and no observed liver safety concerns 2 With global CIndU [...]
Le KFSH fait progresser les applications pratiques de l’IA pour transformer les soins de santé spécialisés
12/06/2026
RIYAD, Arabie saoudite, 12 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) mettra en avant ses applications pratiques de l’intelligence artificielle lors de sa participation [...]
Evaxion receives Prix Galien UK Award for Best digital health solution
12/06/2026
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien [...]
EAACI Calls for a "Vision Zero" Future Free from Allergy and Asthma Burden
12/06/2026
Leading allergy experts to convene in Istanbul to explore how science, prevention and policy can reduce the global impact of allergic diseases ZURICH, June 12, 2026 (GLOBE NEWSWIRE) -- As allergic diseases continue to [...]
Gen Z Is Redefining the Medical Aesthetics Patient Journey, New Guidepoint Qsight Study Finds
12/06/2026
New York, NY, June 11, 2026 (GLOBE NEWSWIRE) -- Leaping Straight to Neurotoxin Treatments like Botox and Dysport, NextGen Medical Aesthetics Patients Frequently Skip Lower Commitment Services Qsight patient transaction [...]
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
12/06/2026
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently [...]
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
12/06/2026
DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for [...]
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
11/06/2026
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. [...]
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
11/06/2026
In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to [...]
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
11/06/2026
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, [...]
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
11/06/2026
Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accretive: expected to [...]
LifeLabs Recognized Once Again by Forbes as One of Canada’s Best Employers for 2026
11/06/2026
Toronto, Ontario, June 11, 2026 (GLOBE NEWSWIRE) -- LifeLabs is proud to announce that we have been named as one of Canada’s Best Employers for 2026 by Forbes Canada. This award is determined by an independent survey of [...]

Pages